Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays a protective role in controlling pancreatic cancer progression, reports a new study from researchers at The University of Texas MD Anderson Cancer Center. This new understanding supports novel therapeutic approaches that bolster collagen rather than suppress it. <...

Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges...
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III...
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents...

The University of Texas MD Anderson Cancer Center is proud to support World Cancer Day, Feb. 4, to honor the international effort to eliminate...
Emil J Freireich, M.D., a trailblazing oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized...
The University of Texas MD Anderson Cancer Center today launched a pivotal, multi-year Strategy aimed at making the greatest impact on humanity...
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell...
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University...
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas...